Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: April 2, 2026, 4:10 am
Author: Getaka|Social: XLinkedIn
Stock Ticker - BSE: 530233 | NSE: AUROLAB

Auro Laboratories Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹141.76Overvalued by 47.88%vs CMP ₹272.00

P/E (57.4) × ROE (4.3%) × BV (₹69.90) × DY (2.00%)

₹134.72Overvalued by 50.47%vs CMP ₹272.00
MoS: -101.9% (Negative)Confidence: 53/100 (Moderate)Models: 1 Under, 5 Over
ModelCategoryValueWeightSignal
PE-ROEEarnings₹142.8733%Over (-47.5%)
Graham NumberEarnings₹86.3424%Over (-68.3%)
Net Asset ValueAssets₹70.1411%Over (-74.2%)
Earnings YieldEarnings₹47.4011%Over (-82.6%)
ROCE CapitalReturns₹385.0213%Under (+41.6%)
Revenue MultipleRevenue₹31.228%Over (-88.5%)
Consensus (6 models)₹134.72100%Overvalued
Key Drivers: ROE 4.3% is below cost of equity. | Wide model spread (₹31–₹385) — high uncertainty.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: 0.8%

*Investments are subject to market risks

Investment Snapshot

54
Auro Laboratories Ltd scores 54/100 (Average)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health50/100 · Moderate
ROCE 3.9% WeakROE 4.3% WeakD/E 0.07 Low debtInterest Coverage 0.0x RiskyProfitable 5/5 years Consistent
Smart Money50/100 · Moderate
Promoter holding at 52.2% Stable
Earnings Quality75/100 · Strong
OPM expanding (9% → 19%) ImprovingWorking capital: -14 days (improving) Efficient
Quarterly Momentum60/100 · Moderate
Revenue (4Q): +19% YoY GrowingProfit (4Q): -15% YoY DecliningOPM: 43.2% (up 28.5% YoY) Margin expansion
Industry Rank20/100 · Weak
P/E 57.4 vs industry 53.8 In-lineROCE 3.9% vs industry 16.4% Below peersROE 4.3% vs industry 15.2% Below peers3Y sales CAGR: -27% Shrinking

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Auro Laboratories Ltd Investor Signals

Computed from valuation, cash flow, balance sheet, ownership and quarterly trend data already available in this stock page.

Value Trap Score
30/100
Low
Derived from: Cheapness + weak quality + weak cash support
Current data: P/E 57.4 vs Ind 53.8 | ROCE 3.9% | ROE 4.3% | CFO/NP N/A
Balance Sheet Stress
20/100
Comfortable
Derived from: Leverage + debt servicing + liquidity + debt trend
Current data: D/E 0.07x | IntCov 0.0x | Current 3.32x | Borrow/Reserve 1.18x
Cash Flow Reliability
43/100
Mixed
Derived from: Cash backing of earnings + working capital pressure
Current data: CFO ₹0 Cr | NP ₹2 Cr | CFO/NP N/A
Ownership Accumulation
0
Neutral
Derived from: FII + DII + promoter direction, adjusted by crowding
Current data: FII N/A | DII 0.00 pp | Prom 0.00 pp
Business Momentum
+100
Stable
Derived from: Latest quarter sales + profit + OPM change
Current data: Q Sales +6.2% | Q NP +170.8% | Q OPM +16.7 pp
Derived FieldValueHow it is derived
Valuation Gap %-50.5%((Fair Value - CMP) / CMP) × 100
Borrowings / Reserves1.18xLatest borrowings divided by latest reserves
CFO / Net ProfitN/ALatest operating cash flow divided by latest net profit
FII ChangeN/ALatest FII% minus previous FII%
DII Change0.00 ppLatest DII% minus previous DII%
Promoter Change0.00 ppLatest promoter% minus previous promoter%
Shareholder Count Change-220Latest shareholder count minus previous count
Quarterly Sales Change+6.2%Latest quarter sales vs previous quarter sales
Quarterly Profit Change+170.8%Latest quarter net profit vs previous quarter net profit
Quarterly OPM Change+16.7 ppLatest quarter OPM minus previous quarter OPM

Share Price and Basic Stock Data

Last Updated: April 2, 2026, 4:10 am

Market Cap 169 Cr.
Current Price 272
Intrinsic Value₹134.72
High / Low 317/159
Stock P/E57.4
Book Value 69.9
Dividend Yield0.00 %
ROCE3.85 %
ROE4.33 %
Face Value 10.0
PEG Ratio73.85

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Auro Laboratories Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Auro Laboratories Ltd 169 Cr. 272 317/15957.4 69.90.00 %3.85 %4.33 % 10.0
Lyka Labs Ltd 183 Cr. 51.2 129/44.1 28.30.00 %9.91 %9.31 % 10.0
Aarey Drugs & Pharmaceuticals Ltd 151 Cr. 53.3 100/41.144.0 52.50.00 %6.38 %2.96 % 10.0
Nectar Lifescience Ltd 190 Cr. 9.76 28.3/9.20 32.00.00 %5.36 %11.2 % 1.00
Coral Laboratories Ltd 137 Cr. 383 785/3609.57 5960.39 %17.4 %13.1 % 10.0
Industry Average19,815.15 Cr1,053.8453.84201.200.39%16.35%15.16%6.10

All Competitor Stocks of Auro Laboratories Ltd

Quarterly Result

MetricDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales 15.6213.5210.1813.4117.9812.065.723.103.057.402.778.849.39
Expenses 15.1711.179.0210.3813.909.654.392.382.606.592.746.495.33
Operating Profit 0.452.351.163.034.082.411.330.720.450.810.032.354.06
OPM % 2.88%17.38%11.39%22.60%22.69%19.98%23.25%23.23%14.75%10.95%1.08%26.58%43.24%
Other Income 0.430.620.360.320.420.400.200.310.140.130.420.980.18
Interest 0.100.130.270.350.44-0.320.250.280.250.300.280.961.52
Depreciation 0.270.300.270.270.270.280.270.270.270.290.270.650.98
Profit before tax 0.512.540.982.733.792.851.010.480.070.35-0.101.721.74
Tax % 27.45%29.53%27.55%27.84%27.70%18.60%24.75%25.00%28.57%-11.43%0.00%58.14%-12.07%
Net Profit 0.371.780.711.972.732.320.750.360.050.39-0.110.721.95
EPS in Rs 0.592.861.143.164.383.721.200.580.080.63-0.181.163.13

Last Updated: March 3, 2026, 12:04 pm

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 26, 2026, 11:30 pm

MetricMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 33.7432.6527.9135.4740.7946.8243.7954.2550.8752.8953.6419.4028.40
Expenses 30.9529.7125.1131.0334.4339.8337.5143.0146.2448.5042.9616.0021.15
Operating Profit 2.792.942.804.446.366.996.2811.244.634.3910.683.407.25
OPM % 8.27%9.00%10.03%12.52%15.59%14.93%14.34%20.72%9.10%8.30%19.91%17.53%25.53%
Other Income 0.060.240.420.530.510.960.970.761.090.941.500.661.71
Interest 1.531.661.661.181.210.870.580.460.830.810.741.083.06
Depreciation 0.740.720.680.860.931.011.021.041.021.071.091.102.19
Profit before tax 0.580.800.882.934.736.075.6510.503.873.4510.351.883.71
Tax % 0.00%0.00%0.00%72.01%25.16%27.51%27.96%31.62%26.61%28.99%24.64%2.13%
Net Profit 0.580.800.880.823.534.404.057.182.842.447.791.842.95
EPS in Rs 0.931.281.411.325.667.066.5011.524.563.9112.502.954.74
Dividend Payout % 0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)37.93%10.00%-6.82%330.49%24.65%-7.95%77.28%-60.45%-14.08%219.26%-76.38%
Change in YoY Net Profit Growth (%)0.00%-27.93%-16.82%337.31%-305.84%-32.60%85.24%-137.73%46.36%233.35%-295.64%

Auro Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:-5%
5 Years:-15%
3 Years:-27%
TTM:-67%
Compounded Profit Growth
10 Years:9%
5 Years:-15%
3 Years:-13%
TTM:-91%
Stock Price CAGR
10 Years:34%
5 Years:33%
3 Years:42%
1 Year:23%
Return on Equity
10 Years:15%
5 Years:13%
3 Years:11%
Last Year:4%

Last Updated: September 5, 2025, 2:31 pm

Balance Sheet

Last Updated: December 10, 2025, 3:52 am

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 6.236.236.236.236.236.236.236.236.236.236.236.236.23
Reserves 0.671.472.353.186.7511.1815.2722.3525.2927.9735.7336.7437.35
Borrowings 14.8016.4112.624.959.208.093.163.1613.786.4126.2542.7243.94
Other Liabilities 5.144.674.4912.458.237.977.6810.159.6615.3817.5213.4023.25
Total Liabilities 26.8428.7825.6926.8130.4133.4732.3441.8954.9655.9985.7399.09110.77
Fixed Assets 10.519.809.1313.0013.0214.5914.2413.5613.6112.6222.1521.0676.84
CWIP 0.060.823.330.231.070.120.120.133.687.6732.6856.4810.37
Investments 0.050.050.050.050.050.050.050.050.050.050.050.050.05
Other Assets 16.2218.1113.1813.5316.2718.7117.9328.1537.6235.6530.8521.5023.51
Total Assets 26.8428.7825.6926.8130.4133.4732.3441.8954.9655.9985.7399.09110.77

Reserves and Borrowings Chart

Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + 4.48-0.787.886.496.056.879.3012.82-6.593.2818.815.75
Cash from Investing Activity + -0.56-0.73-2.44-2.20-3.04-3.19-2.21-3.51-5.34-5.08-38.67-24.45
Cash from Financing Activity + -2.990.53-5.34-3.81-1.77-1.83-5.52-0.469.79-8.1819.0917.69
Net Cash Flow 0.93-0.980.090.471.241.861.588.85-2.14-9.98-0.77-1.02
Free Cash Flow 3.86-1.555.364.864.255.258.6312.44-11.20-0.7918.815.75
CFO/OP 161%-27%281%146%95%98%148%114%-142%75%176%169%

Free Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow-12.01-13.47-9.82-0.51-2.84-1.103.128.08-9.15-2.02-15.57-39.32

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 46.9594.8066.0479.1374.9066.2648.1849.1297.6585.5791.11176.67
Inventory Days 115.3389.3786.7221.6522.0042.9860.5432.6047.32120.27113.24145.45
Days Payable 62.9756.1272.0380.2678.2666.1970.6773.5154.12117.4185.34246.11
Cash Conversion Cycle 99.30128.0580.7320.5218.6443.0538.048.2090.8688.44119.0176.01
Working Capital Days 19.1539.1326.6867.2064.7063.4651.0929.4036.59104.2835.86-14.30
ROCE %9.43%10.74%11.21%23.06%32.51%29.11%24.84%38.87%12.20%9.92%20.38%3.85%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 52.09%52.09%52.09%52.09%52.15%52.15%52.15%52.15%52.17%52.17%52.17%52.17%
DIIs 0.01%0.01%0.01%0.01%0.01%0.01%0.01%0.01%0.01%0.01%0.01%0.01%
Public 47.90%47.90%47.92%47.90%47.85%47.84%47.84%47.84%47.82%47.82%47.82%47.80%
No. of Shareholders 10,90610,50110,2729,9059,4419,3359,2669,2659,1028,9168,8608,640

Shareholding Pattern Chart

No. of Shareholders

Auro Laboratories Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

This stock is not held by any mutual fund.

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 10.0010.0010.0010.0010.00
Basic EPS (Rs.) 2.9512.503.924.5611.52
Diluted EPS (Rs.) 2.9512.503.924.5611.52
Cash EPS (Rs.) 4.7114.265.646.2013.18
Book Value[Excl.RevalReserv]/Share (Rs.) 68.9467.3254.8750.5845.86
Book Value[Incl.RevalReserv]/Share (Rs.) 68.9467.3254.8750.5845.86
Revenue From Operations / Share (Rs.) 31.1286.0684.8781.6187.05
PBDIT / Share (Rs.) 6.5119.538.569.1719.25
PBIT / Share (Rs.) 4.7517.786.837.5417.59
PBT / Share (Rs.) 3.0216.605.536.2116.86
Net Profit / Share (Rs.) 2.9512.503.924.5611.52
PBDIT Margin (%) 20.9222.6910.0811.2422.11
PBIT Margin (%) 15.2720.668.059.2420.20
PBT Margin (%) 9.6919.286.517.6119.36
Net Profit Margin (%) 9.4714.524.615.5913.23
Return on Networth / Equity (%) 4.2718.577.149.0225.11
Return on Capital Employeed (%) 3.8217.9311.2513.4932.80
Return On Assets (%) 1.859.084.365.1717.13
Long Term Debt / Equity (X) 0.710.430.050.020.07
Total Debt / Equity (X) 0.990.620.180.020.07
Asset Turnover Ratio (%) 0.200.750.951.051.46
Current Ratio (X) 0.991.291.971.873.32
Quick Ratio (X) 0.820.941.321.663.02
Inventory Turnover Ratio (X) 3.262.904.669.928.30
Interest Coverage Ratio (X) 3.7516.556.556.9226.18
Interest Coverage Ratio (Post Tax) (X) 2.7011.594.004.4416.66
Enterprise Value (Cr.) 185.78125.0337.8050.9738.05
EV / Net Operating Revenue (X) 9.582.330.711.000.70
EV / EBITDA (X) 45.7610.277.098.913.17
MarketCap / Net Operating Revenue (X) 7.411.870.641.230.93
Price / BV (X) 3.342.390.991.981.77
Price / Net Operating Revenue (X) 7.411.870.641.230.93
EarningsYield 0.010.070.070.040.14

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

Auro Laboratories Ltd. is a Public Limited Listed company incorporated on 26/05/1989 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L33125MH1989PLC051910 and registration number is 051910. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 19.40 Cr. and Equity Capital is Rs. 6.23 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
PharmaceuticalsK-56, M.I.D.C. Industrial Area, Palghar District Maharashtra 401506Contact not found
Management
NamePosition Held
Mr. Sharat DeorahChairman & Managing Director
Mr. Kiran Suresh KulkarniWhole Time Director
Mr. Siddhartha DeorahWhole Time Director
Mr. Mahendra Kumar DagaInd. Non-Executive Director
Mrs. Kavita Vijayakant SharmaInd. Non-Executive Director
Mr. Vishal Kailashchandra JhunjhunwalaInd. Non-Executive Director

FAQ

What is the intrinsic value of Auro Laboratories Ltd and is it undervalued?

As of 05 April 2026, Auro Laboratories Ltd's intrinsic value is ₹134.72, which is 50.47% lower than the current market price of ₹272.00, suggesting the stock is overvalued. This is calculated using the PE ratio method factoring in ROE (4.33 %), book value (₹69.9), dividend yield (0.00 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Auro Laboratories Ltd?

Auro Laboratories Ltd is trading at ₹272.00 as of 05 April 2026, with a FY2026-2027 high of ₹317 and low of ₹159. The stock is currently in the middle of its 52-week range. Market cap stands at ₹169 Cr..

How does Auro Laboratories Ltd's P/E ratio compare to its industry?

Auro Laboratories Ltd has a P/E ratio of 57.4, which is above the industry average of 53.84. The premium over industry average may reflect growth expectations or speculative interest.

Is Auro Laboratories Ltd financially healthy?

Key indicators for Auro Laboratories Ltd: ROCE of 3.85 % is on the lower side compared to the industry average of 16.35%; ROE of 4.33 % is below ideal levels (industry average: 15.16%). Dividend yield is 0.00 %.

Is Auro Laboratories Ltd profitable and how is the profit trend?

Auro Laboratories Ltd reported a net profit of ₹2 Cr in Mar 2025 on revenue of ₹19 Cr. Compared to ₹3 Cr in Mar 2022, the net profit shows a declining trend.

Does Auro Laboratories Ltd pay dividends?

Auro Laboratories Ltd has a dividend yield of 0.00 % at the current price of ₹272.00. The company is currently not paying meaningful dividends.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Auro Laboratories Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports